U.S. approves $2 million Novartis gene therapy for rare, deadly muscle disorder
ZURICH/NEW YORK - Swiss drugmaker Novartis won U.S. approval for its gene therapy Zolgensma for spinal muscular atrophy (SMA), the leading genetic cause of death in infants, the company said on Friday, a one-time treatment expected to push the pricing boundary for rare diseases to new heights.
from Reuters: Health News https://reut.rs/2W3Q4ve
http://bit.ly/2zwRqiM